Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate Plc (NYSE: CLVT) announced the winners of the 2020 Revenue Cycle Awards, recognizing healthcare organizations for outstanding performance in revenue cycle KPIs. The winners include ThedaCare (WI), University of Iowa Hospitals & Clinics (IA), and Essentia Health (MN). Award recipients adapted to pandemic challenges, enhancing operations to support staff and patients. Winners demonstrated top decile performance metrics, including first-pass appeal success rates and online payment percentages, showcasing effective revenue cycle management amidst the COVID-19 crisis.
Clarivate Plc (NYSE: CLVT) reported strong results for Q1 2021, with revenues of $428.4 million, up 78% year-over-year. Adjusted revenues also increased by 78% to $431.5 million. Organic revenues rose 7%, driven by a 6% increase in subscription revenues and a 10% rise in transactional revenues. However, the company faced a GAAP loss from operations of $34.2 million, up 21%. Adjusted EBITDA surged 111% to $164.8 million. Cash from operations was $174 million, significantly higher than the previous year. The company updated its 2021 outlook to forecast 6% to 8% organic growth.
Clarivate Plc (NYSE: CLVT) announced enhancements to its Cortellis Deals Intelligence, introducing new deal trend visualizations and predictive analytics powered by artificial intelligence. These tools aim to streamline the assessment of potential net present value (NPV) for in-licensing candidates in drug development. The integration of real-time data allows users to make informed decisions and better estimate deal sizes. Notably, biopharma deal-making reached record levels in 2020, with nearly $200 billion in transactions.
Clarivate Plc (NYSE: CLVT) has appointed Julie Wilson as the new Chief People Officer, succeeding Andrea Degutis, who retires after four years. This leadership transition occurs during a period of significant growth and transformation for the company. CEO Jerre Stead acknowledged Degutis's vital contributions, especially during the pandemic. Wilson, formerly at Cerner Corporation, brings extensive experience in talent management and a commitment to a high-performance culture. Clarivate aims to enhance employee engagement and profitability while positioning itself as one of the world's best workplaces.
Clarivate Plc (NYSE: CLVT) has released a report highlighting the significant growth of research output in the MENAT region, which has increased from 2% to 8% of global research over the last 40 years. The report identifies Egypt as a key player with 60% international collaboration, while Iran has surpassed other countries in the region to become the largest research producer. Despite high global collaboration, regional collaboration remains low. The study emphasizes the potential for enhanced local collaboration to improve research quality and international competitiveness.
Clarivate Plc (NYSE: CLVT) announced that Jerre Stead, Executive Chairman and CEO, and Richard Hanks, CFO, will present at the BofA Securities 2021 Information Services Conference on March 18, 2021, at 3:35 PM Eastern Time. A live webcast of the presentation will be accessible on the Investor Relations section of Clarivate's website, with a replay available for 30 days post-event. Clarivate aims to accelerate innovation by providing actionable information and insights to help clients navigate complex challenges.
Clarivate Plc (NYSE:CLVT) released its annual 'Drugs to Watch' list, spotlighting potential blockbuster drugs that could exceed $1 billion in sales by 2025. Highlighted drugs include Aducanumab for Alzheimer's, which could revolutionize treatment; Bimekizumab for psoriasis, offering improved efficacy; Relugolix, an oral treatment for prostate cancer; and Vericiguat for heart failure. The report reflects the accelerated pace of biopharma innovation, driven by insights from COVID-19 developments, faster trials, and increased investment in research and development.
Clarivate Plc (NYSE: CLVT) has launched the Web of Science™ Author Impact Beamplots, an innovative tool that visualizes a researcher's publication and citation impact comprehensively. Unlike traditional metrics, beamplots provide a normalized citation count, offering deeper insights into researchers' performance over time. This tool aims to facilitate responsible research evaluation by emphasizing contextual factors such as collaboration and research type. Experts highlight that this method combines quantitative and qualitative indicators for a fairer assessment of researcher contributions.
Clarivate Plc (NYSE: CLVT) announced its participation in the Morgan Stanley Technology, Media and Telecom Conference on March 4, 2021, at 9:30 AM Eastern Time. The presentation will be led by Jerre Stead, Executive Chairman and CEO, alongside Richard Hanks, CFO. A live webcast will be accessible on the Investor Relations section of the Clarivate website, with a replay available for 30 days following the event. Clarivate focuses on providing trusted information and insights to enhance innovation across various sectors.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
